Impact of Lipid-Lowering Combination Therapy With Statins and Ezetimibe vs Statin Monotherapy on the Reduction of Cardiovascular Outcomes: A Meta-analysis

2025/03/23 by Maciej Banach, Vikash Jaiswal, Song Peng Ang +12 · 18 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Cancer, Lipids, and Metabolism #Combination therapy #Diabetes, Cardiovascular Risks, and Lipoproteins #Ezetimibe #Hydroxymethylglutaryl-CoA Reductase Inhibitors #Internal medicine #Lipoproteins and Cardiovascular Health #Medicine #Meta-analysis #Pharmacology #Statin

paper · doi:10.1016/j.mayocp.2025.01.018

published in Mayo Clinic Proceedings 100(12), 2152-2171 (Elsevier BV)

openalex publication_date 2025/03/23 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/06

Citations

• Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association

Cited by

• Are we underestimating the benefits of lipid-lowering therapies?
• Rosuvastatin-based combination treatment with acetylsalicylic acid or ezetimibe in the management of patients at high and very high cardiovascular risk. Expert opinion paper of the Polish Lipid Association 2025. [europepmc]
• A Comprehensive Review of the Latest Approaches to Managing Hypercholesterolemia: A Comparative Analysis of Conventional and Novel Treatments: Part I. [europepmc]
• Low-Density Lipoprotein Cholesterol Target Attainment in Lithuania: A Nationwide Analysis of Real-World Health Data. [europepmc]
• WHF Roadmap on Single Pill Combination Therapies. [europepmc]
• Determinants of lack of atherosclerosis progression in adult patients with elevated lipoprotein (a): results from the STAR-Lp(a) study. [europepmc]
• Cardiovascular outcomes and adverse drug reactions associated with the use of ezetimibe in combination with a statin in diabetes mellitus patients with higher risk for myocardial infarction: a meta-analysis. [europepmc]
• Molecular Mechanisms Underlying Atherosclerosis and Current Advances in Targeted Therapeutics. [europepmc]
• Statin treatment in routine clinical practice: Insights from the STATRIP physician survey. [europepmc]
• Real-world changes in lipid-lowering therapy use and LDL-C goal attainment in high and very high cardiovascular risk patients in the UK: a secondary analysis of the European SANTORINI study 1-year follow-up. [europepmc]
• Advancing Lipid Management: Saudi Heart Association Position Statement on PCSK9-targeted Therapies in the Primary and Secondary Prevention of Cardiovascular Disease. [europepmc]
• Efficacy and Safety of Inclisiran—An Assessment of the Consistency Between Randomized Controlled Trials and Real-World Evidence: A Systematic Review [europepmc]